Sei Investments CO Tcr2 Therapeutics Inc. Transaction History

Sei Investments CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $390,815 - $711,660	-85,331 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $906,658 - $1.97 Million	-107,424 Reduced 55.73%	85,331 $726,000
Q2 2021 Aug 06, 2021	BUY	$16.41 - $24.71 $620,527 - $934,383	37,814 Added 24.41%	192,755 $3.16 Million
Q1 2021 May 12, 2021	SELL	$20.38 - $34.07 $1.37 Million - $2.29 Million	-67,168 Reduced 30.24%	154,941 $3.42 Million
Q4 2020 Feb 08, 2021	BUY	$19.0 - $32.63 $4.22 Million - $7.25 Million	222,109 New	222,109 $6.87 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.